肾癌患者血清VHL HIF-1α HIF-2α水平变化及意义

doi:10.3969/j.issn.1006-6233.2018.01.008

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1279 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To research the changes and significance of serum von hippel-lindau (VHL), hypoxia-inducible factor (HIF)-1α and HIF-2α in patients with renal cancer. Method: 45 cases of renal carcinoma were collected from January 2015 to April 2016 as the renal cell cancer group, and at the same time the collection of healthy persons as control group, serum VHL, HIF-1α and HIF-2α level of two groups were examined; The maximum diameter of renal cancer patients was measured; Patients with renal cell carcinoma were followed up for 6 months, observed and recorded the recurrence patients. Results: The level of serum VHL in renal cancer group decreased significantly compared with that in control group, while levels of HIF-1α and HIF-2α were obviously higher( P<0.01) . Expression of serum VHL, HIF-1α and HIF-2α was not related to age and sex in renal carcinoma (P>0. 05) ,while there was significantly correlated with pathological grade, clinical stages, diameter of cancer site and lym-phatic metastasis (P<0.01). Level of serum VHL in recurrent cases was obviously lower, while levels of HIF-1α and HIF-2α were obviously higher than non-recurrent cases( P< 0.05,P<0.01) . Conclusion: Levels of serum VHL, HIF-1α and HIF-2α are correlated significantly with pathological grade, clinical stages, size of carcinoma and lymphatic metastasis, which indicates indexes mentioned above could be play an important role in the occurrence and development of clear cell renal carcinoma.

Key words： Renal carcinoma VHL HIF-1α HIF-2α

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Chunxia
	LI Zhongxin
	LIU Yongquan
	et al

Cite this article:

SHI Chunxia,LI Zhongxin,LIU Yongquan, et al. The Level Changes and Significance of Serum VH HIF-1α and HIF-2α Levels in Patients with Kidney Cancer[J]. HeBei Med, 2018, 24(1): 34-38.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.01.008 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I1/34

[1] 陈铌,周桥.肾细胞癌的病理诊断与研究进展[J].现代泌尿外科杂志,2016,21(3):164~169.
[2] 范俊.不同手术方案治疗老年T₂期肾细胞癌的疗效及安全性比较[J].中国老年学,2017,37(5):1168~1169.
[3] 吴俊伸,刘仕杰,余飞,等.肾癌循环肿瘤细胞检测及临床价值的研究进展[J].现代泌尿外科杂志,2017,22(6):474~477.
[4] 刘长姣,李明春.肾癌靶向治疗及联合用药的研究进展[J].中国医院药学杂志,2017,37(7):666~669.
[5] 田立志,沈阳,项鹏程,等.缺氧诱导因子与肾细胞癌关系的研究进展[J].现代生物医学进展,2015,15(1):188~190.
[6] Xu J, Sadahira T, Kinoshita R, et al. Exogenous DKK-3/REIC inhibits Wnt/β-catenin signaling and cell proliferation in human kidney cancer KPK1[J]. Oncol Lett,2017,14(5):5638~5642.
[7] Gorin MA, Rowe SP. Kidney cancer: PSMA: a potential therapeutic target in RCC[J]. Nat Rev Urol,2017,14(11):646~647.
[8] Kozlowski L, Kozowska K, et al. Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine[J]. Oncotarget,2017,8(39):66601~66619.
[9] Diaz de Leon A, Pedrosa I. Imaging and Screening of Kidney Cancer[J]. Radiol Clin North Am,2017,55(6):1235~1250.
[10] Hamano I, Hatakeyama S, Iwamurau H, et al. Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer[J]. Oncotarget,2017,8(37):61404~61414.
[11] 王毓斌,邵晋凯,李晓东,等.肾癌患者外周血循环内皮祖细胞与血清血管内皮生长因子的表达分析[J].中国医师进修杂志,2016,39(11):965~968.
[12] 贾志凌,杨永昌,张淑艳,等.血管内皮生长因子诊断多种恶性肿瘤临床价值[J].中华实用诊断与治疗杂志,2015,29(7):701~702.
[13] 刘锐,裴强,李伟,等.肾癌患者血清VEGF的水平及其与临床病理分期的关系[J].现代生物医学进展,2016,16(21):4065~4067.
[14] 程鑫宇,吴小荣,刘东明.肾癌中VHL基因的研究进展[J].生命的化学,2015,35(2):176~182.
[15] 刘俊,崔龙.肾癌患者血清VHL、HIF-1α和HIF-2α的表达及临床意义[J].实用癌症杂志,2016,31(6):895~898.
[16] 苗龙,刘洋,刘林,等.肾细胞癌组织中PTEN和HIF-1α的表达及临床意义[J].现代生物医学进展,2017,17(6):1127~1130.
[17] 张志刚,叶烈夫,林乐,等.人抗原R与乏氧诱导因子1α在肾细胞癌中的表达及临床意义[J].中华泌尿外科杂志,2014,35(4):262~266.
[18] 蔡利忠,邢伟,陈杰,等.BOLD-MRI评价肾透明细胞癌HIF-α表达的可行性研究[J].临床放射学杂志,2016,35(4):585~588.